<DOC>
	<DOCNO>NCT02909556</DOCNO>
	<brief_summary>Cinical trial aim evaluate safety performance ACURATE neo™ AS Aortic Bioprosthesis ACURATE neo™ AS TF Transfemoral Delivery System CE mark approval purpose .</brief_summary>
	<brief_title>ACURATE Neo™ AS Aortic Bioprosthesis Implantation Using ACURATE neoTM AS TF Transfemoral Delivery System Patients With Severe Aortic Stenosis</brief_title>
	<detailed_description>Single arm , prospecitve , multicenter , non-randomized open trial . The purpose trial collect safety performance data concern ACURATE neo™ AS Aortic Bioprosthesis ACURATE neo™ AS TF Transfemoral Delivery System The ACURATE neo™ AS Aortic Bioprosthesis ACURATE neo™ AS TF Transfemoral Delivery SystemACURATE neo™ intend use minimally invasive , transcatheter aortic valve replacement ( TAVR ) use transfemoral access patient present severe aortic valve stenosis . The primary objective evaluate safety performance study device patient present severe aortic stenosis ( AS ) consider high risk surgery . The secondary objective evaluate adverse event study device performance .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Patient 75 year age old 2 . Severe aortic stenosis define : Mean aortic gradient &gt; 40 mmHg Peak jet velocity &gt; 4.0 m/s Aortic valve area &lt; 1.0 cm2 3 . High risk candidate conventional AVR define : Logistic EuroSCORE 1 ≥ 20 % STS Score ≥ 8 % Heart team ( cardiologist cardiac surgeon ) consensus patient surgical candidate conventional AVR due significant comorbid condition unrelated aortic stenosis 4 . NYHA Functional Class &gt; II 5 . Aortic annulus diameter ≥ 21mm ≤ 27mm CT 6 . Patient willing participate study provide sign informed consent 1 . Congenital aortic stenosis unicuspid bicuspid aortic valve 2 . Nonstenotic Aortic Insufficiency 3 . Severe eccentricity calcification 4 . Severe mitral regurgitation ( &gt; 2+ ) 5 . Presence mitral bioprosthesis 6 . Presence previously implant aortic bioprosthesis 7 . Presence prosthetic ring 8 . Anatomy NOT appropriate transfemoral implant due size , disease degree calcification tortuosity aorta iliofemoral artery 9 . Thoracic ( TAA ) abdominal ( AAA ) aortic aneurysm 10 . Presence endovascular stent graft treatment TAA AAA 11 . Transoesophageal echocardiogram ( TEE ) contraindicate 12 . Evidence intracardiac mass , thrombus vegetation 13 . Severe ventricular dysfunction ejection fraction &lt; 20 % 14 . Any percutaneous intervention , except balloon valvuloplasty ( BAV ) within 1 month prior implant procedure 15 . Acute Myocardial Infarction within 1 month prior implant procedure 16 . Previous TIA stroke within 3 month prior implant procedure 17 . Active ulcer gastrointestinal ( GI ) bleed within 3 month prior implant procedure 18 . Any scheduled surgical percutaneous procedure perform prior 30 day visit 19 . Severe coagulation condition 20 . Refusal blood transfusion 21 . Systolic pressure &lt; 80mmHg , cardiogenic shock , need inotropic support IABP 22 . Hypertrophic cardiomyopathy without obstruction 23 . Active bacterial endocarditis active infection 24 . Hepatic failure ( &gt; Child B ) 25 . Chronic renal dysfunction serum creatinine &gt; 2.5 mg/dL renal dialysis 26 . Refusal surgery 27 . Severe COPD require home oxygen 28 . Neurological disease severely affect ambulation daily function , dementia 29 . Life expectancy &lt; 12 month due noncardiac comorbid condition 30 . Inability tolerate anticoagulation therapy 31 . Contraindication contrast medium allergy nickel 32 . Currently participate investigational drug another device study 33 . Nonvalvular aortic stenosis 34 . Noncalcific acquire aortic stenosis</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Transcatheter Aortic Valve Replacement</keyword>
	<keyword>TAVI</keyword>
	<keyword>Transcatheter Aortic Valve Implant</keyword>
	<keyword>Transfemoral access</keyword>
</DOC>